Papillon CXB Clinical Engagement Across India & Sri Lanka

/in , , /by

Papillon CXB Clinical Engagement Across India & Sri Lanka

Mark Davies-Cousins – VP International Sales

Mark Davies-Cousins, VP International Sales at Ariane Medical Systems, recently completed an extensive clinical knowledge-sharing initiative across India and Sri Lanka, delivered between 29th January and 12th February 2026.

The programme formed part of Ariane’s ongoing commitment to supporting clinical education, strengthening partnerships, and expanding access to Papillon Contact X-ray Brachytherapy (CXB) technology across key international markets.

The visit began with participation in the Medical Fair India 2026 in New Delhi, before continuing with a series of clinical engagements across leading healthcare institutions.

India & Sri Lanka Itinerary 2026

10th – 12th February | Colombo, Sri Lanka

29th – 31st January | New Delhi
Medical Fair India – Bharat Mandapam (Pragati Maidan)

1st – 3rd February | Mumbai
Tata Memorial Hospital, Tata Cancer Care Foundation, Asian Cancer Institute,
HN Reliance Hospital, Hinduja Hospital

4th February | Hyderabad
Yashoda Hospitals, Omega Hospitals, AIG Hospitals

5th – 7th February | Chennai
Apollo Hospitals, Cancer Institute Chennai, MIOT International Hospital,
Christian Medical College (Vellore), AROI

9th February | Trivandrum
Regional Cancer Centre

Across all locations, the initiative provided valuable opportunities to present Papillon CXB technology, discuss clinical applications, and engage directly with multidisciplinary teams, including radiation oncologists, surgeons, and medical physicists.

This programme highlights the growing international interest in non-invasive treatment approaches and reinforces Ariane Medical Systems’ commitment to supporting the global adoption of Papillon technology.

First Patient Treatments Delivered at New Centre of Excellence – St Bartholomew’s Hospital, London

/in , , /by

St Bartholomew’s Hospital has successfully delivered its first Papillon Contact X-ray Brachytherapy (CXB) patient treatments, marking a significant milestone in expanding access to this specialist therapy in the UK.

The first patients were treated onsite on 16th January 2026, enabling individuals with lower rectal cancer to access treatment within London for the first time, removing the need to travel to centres such as Liverpool or Hull.

The treatments were supported by Arthur Sun Myint from the Clatterbridge Cancer Centre, who worked alongside Pablo Neclares and the St Bartholomew’s clinical team to deliver the procedures.

While Papillon CXB has been available in the UK for nearly 30 years, with four established sites across England since 2014 and over 5,000 patients treated, St Bartholomew’s Hospital is the first centre in London to offer this technology, and the first new UK site to be introduced since 2014.

Following recent guidance from the National Institute for Health and Care Excellence (NICE) recommending Papillon CXB as a non-surgical treatment option for selected patients, interest in the technology has increased significantly both across the UK and internationally.

This milestone represents an important step forward in improving patient access to organ-preserving, non-invasive treatment options within the capital.

Papillon CXB in the United States

/in , , /by

Papillon CXB in the United States
Redefining Rectal Cancer Care in North America

Interest in Papillon Contact X-ray Brachytherapy (CXB) is experiencing a strong resurgence across North America, driven by emerging clinical evidence and increased focus on organ-preserving treatment approaches.

Recent randomised clinical trials, including the OPERA Trial, have played a key role in reshaping clinical perspectives. Alongside this, guidance from the National Institute for Health and Care Excellence (NICE) in the UK has further reinforced confidence in Papillon CXB as a viable non-surgical option for selected rectal cancer patients.

While Contact X-ray Brachytherapy was first developed in the mid-20th century, its adoption was historically limited by the rise of conventional surgical approaches. Today, advances in technology and clinical understanding have positioned Papillon CXB as a sophisticated, non-invasive alternative—supporting organ preservation, improving patient quality of life, and offering favourable long-term healthcare economics.

Clinical trials and evaluation programmes are now underway at several leading centres of excellence across North America. Ariane Medical Systems is proud to collaborate with these institutions and looks forward to supporting the transition from clinical evaluation to broader implementation.

For further information, please contact:

Mark Davies-Cousins
VP International Sales
📞 +44 (0) 7940 359998
✉️ mark.davies@arianemedicalsystems.com